301 related articles for article (PubMed ID: 10080160)
1. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
3. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
4. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C.
Boeker KH; Haberkorn CI; Michels D; Flemming P; Manns MP; Lichtinghagen R
Clin Chim Acta; 2002 Feb; 316(1-2):71-81. PubMed ID: 11750276
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients.
Ninomiya T; Yoon S; Nagano H; Kumon Y; Seo Y; Kasuga M; Yano Y; Nakaji M; Hayashi Y
Intervirology; 2001; 44(4):227-31. PubMed ID: 11509885
[TBL] [Abstract][Full Text] [Related]
7. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
Zhang BB; Cai WM; Weng HL; Hu ZR; Lu J; Zheng M; Liu RH
World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients.
Larrousse M; Laguno M; Segarra M; De Lazzari E; Martinez E; Blanco JL; León A; Deulofeu R; Miquel R; Milinkovic A; Lonca M; Miró JM; Biglia A; Murillas J; Gatell JM; Mallolas J
J Acquir Immune Defic Syndr; 2007 Nov; 46(3):304-11. PubMed ID: 18172937
[TBL] [Abstract][Full Text] [Related]
11. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis.
Flisiak R; Maxwell P; Prokopowicz D; Timms PM; Panasiuk A
Hepatogastroenterology; 2002; 49(47):1369-72. PubMed ID: 12239944
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C.
Murawaki Y; Ikuta Y; Okamoto K; Koda M; Kawasaki H
J Gastroenterol; 2001 Jun; 36(6):399-406. PubMed ID: 11428586
[TBL] [Abstract][Full Text] [Related]
13. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis.
Murawaki Y; Ikuta Y; Idobe Y; Kawasaki H
J Gastroenterol Hepatol; 1999 Feb; 14(2):138-45. PubMed ID: 10029294
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
16. Evidence for altered hepatic matrix degradation in genetic haemochromatosis.
George DK; Ramm GA; Powell LW; Fletcher LM; Walker NI; Cowley LL; Crawford DH
Gut; 1998 May; 42(5):715-20. PubMed ID: 9659170
[TBL] [Abstract][Full Text] [Related]
17. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV.
Mastroianni CM; Liuzzi GM; D'Ettorre G; Lichtner M; Forcina G; Di Campli NF; Riccio P; Vullo V
HIV Clin Trials; 2002; 3(4):310-5. PubMed ID: 12187505
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis.
George DK; Ramm GA; Walker NI; Powell LW; Crawford DH
J Hepatol; 1999 Jul; 31(1):47-52. PubMed ID: 10424282
[TBL] [Abstract][Full Text] [Related]
20. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology.
Yilmaz Y; Eren F
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):43-46. PubMed ID: 30134384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]